Dr. Rosenberg is Chief of the Atherothrombosis and Coronary Artery Disease Branch at the National Heart, Lung, and Blood Institute, part of the US National Institutes of Health (Bethesda, MD). Dr. Rosenberg obtained his MD from the University of Lyon, France, and is Board certified in Preventive Medicine. He also has an MPH from Johns Hopkins.

Dr. Rosenberg’s main research interests are the design and conduct of large multicenter phase III clinical trials, especially trials of treatment strategies, comparative effectiveness and pragmatic trials. He has led and participated in the development, conduct, analysis and reporting of more than a dozen major international cardiovascular clinical trials. Dr. Rosenberg is actively involved in the design and conduct of NIH supported large multi-sites platform, adaptive therapeutic COVID-related clinical trials